Patient-centered applications extend BioClinica's eHealth platform
BioClinica®, Inc., a specialty clinical trials technology and services provider today announced the creation of the eHealth App xChange™, an alliance channel for disruptive technology innovation across life sciences and healthcare. BioClinica’s eHealth App xChange provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
The App xChange is a key component of the expanding BioClinica Partner Alliance program, a strategic priority led by eClinical President Mukhtar Ahmed. "BioClinica has a culture of innovation within clinical research," said Ahmed. "BioClinica’s eHealth App xChange enables research communities to leverage an ecosystem of integrated mobile and cloud applications for unique patient and consumer engagement, digital medicine, biosensor and scientific analytic capabilities, thereby accelerating pre- and post-approval research while creating efficiency and quality benefits."
Ahmed explained, "Our approach introduces pragmatic industry innovation and provides our customers with an integrated and highly interoperable platform that extends across the entire healthcare research landscape."
BioClinica Global Product Development Senior Vice President Andrew Masters said, "Healthcare research applications like these are a natural fit with our core products and extend the BioClinica platform with source data capture, point of care, electronic patient record, workflow and safety offerings." Masters added, "Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, and we welcome new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space."
Find out more about BioClinica’s eHealth App xChange from Chad Ebner, Director of Channel Sales. Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.